ARTICLE | Company News

Gilead sinks as HCV sales decline

July 26, 2016 7:00 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) fell $7.50 to $81.05 on Tuesday, shedding about $10 billion in market cap. On Monday after market close, it lowered its 2016 guidance and reported 2Q16 earnings showing that its HCV sales have slowed (see BioCentury Extra, July 25). ...